Science MagazineCRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activityScience MagazineTaking advantages of the distinctive enzymatic properties of CRISPR enzymes, Gootenberg et al. developed an improved nucleic acid detect… Continue reading
Science MagazineCRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activityScience MagazineTaking advantages of the distinctive enzymatic properties of CRISPR enzymes, Gootenberg et al. developed an improved nucleic acid detect… Continue reading
Science MagazineThis Week in Science | ScienceScience MagazineFor thousands of years, people in northern China grew wheat, whereas people in southern China farmed rice. The latter required shared labor and coordinated irrigation. Rice cultivation thus … Continue reading
Science MagazineThis Week in Science | ScienceScience MagazineFor thousands of years, people in northern China grew wheat, whereas people in southern China farmed rice. The latter required shared labor and coordinated irrigation. Rice cultivation thus … Continue reading
Science MagazineThis Week in Science | ScienceScience MagazineFor thousands of years, people in northern China grew wheat, whereas people in southern China farmed rice. The latter required shared labor and coordinated irrigation. Rice cultivation thus … Continue reading
Science MagazineCRISPR-Cas12a target binding unleashes indiscriminate single …Science MagazineCRISPR techniques are allowing the development of technologies for nucleic acid detection (see the Perspective by Chertow). Taking advantages of the distinc… Continue reading
Science MagazineCRISPR-Cas12a target binding unleashes indiscriminate single …Science MagazineCRISPR techniques are allowing the development of technologies for nucleic acid detection (see the Perspective by Chertow). Taking advantages of the distinc… Continue reading
Targazyme Presents TZ-102 Cancer Immunotherapy Preclinical Results at the World Orphan Drug CongressGlobeNewswire (press release)CARLSBAD, Calif., April 26, 2018 (GLOBE NEWSWIRE) — Targazyme, Inc. a late clinical-stage biopharmaceutical company develo… Continue reading